The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.g

Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

Publications

Alvarez Cardona A, Hernández Nieto L, Pérez Gómez M, Pedroza Meléndez A, Huerta López JG

[Etoposide desensitization. A case report].

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993). 2010;57(1):33-6

Siderov J, Prasad P, De Boer R, Desai J

Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide.

British journal of cancer. 2002;86(1):12-3

de Souza P, Friedlander M, Wilde C, Kirsten F, Ryan M

Hypersensitivity reactions to etoposide. A report of three cases and review of the literature.

American journal of clinical oncology. 1994;17(5):387-9

O'Dwyer PJ, Weiss RB

Hypersensitivity reactions induced by etoposide.

Cancer treatment reports. 1984;68(7-8):959-61

Kasperek C, Black CD

Two cases of suspected immunologic-based hypersensitivity reactions to etoposide therapy.

The Annals of pharmacotherapy. 1992;26(10):1227-30